These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 468452)

  • 1. Liver size in evaluating drug metabolizing capacity in man.
    Pirttiaho H
    Int J Clin Pharmacol Biopharm; 1979 Jun; 17(6):271-6. PubMed ID: 468452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
    Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
    Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Quantification of the drug-metabolizing enzyme system in liver diseases: a comparison between antipyrine saliva clearance and the aminopyrine breath test].
    von Mandach U; Jost G; Preisig R
    Schweiz Med Wochenschr; 1985 May; 115(19):651-8. PubMed ID: 3923620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monooxigenase activity in liver diseases (study based on data of antipyrine metabolism)].
    Loginov AS; Bendikov EA; Kel'nia ZhA; Petrakov AV
    Ter Arkh; 1987; 59(2):84-9. PubMed ID: 3576485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The antipyrine test in occupational medicine research--evaluation of individual reproducibility and frequency distribution of half-life].
    Uhlig H; Damrau J; Skölziger R
    Z Gesamte Hyg; 1989 Feb; 35(2):82-4. PubMed ID: 2741499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exercise training does not alter cytochrome P-450 content and microsomal metabolism.
    Michaud TJ; Bachmann KA; Andres FF; Flynn MG; Sherman GP; Rodriguez-Zayas J
    Med Sci Sports Exerc; 1994 Aug; 26(8):978-82. PubMed ID: 7968432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlations between cytochrome P-450 and oxidative metabolism of benzo[a]pyrene and 7-ethoxycoumarin in human liver in vitro and antipyrine elimination in vivo.
    Pelkonen O; Sotaniemi E; Tokola O; Ahokas JT
    Drug Metab Dispos; 1980; 8(4):218-22. PubMed ID: 6105054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-adrenoceptor blocking drugs and cytochrome P-450: the influence of propranolol treatment on caffeine, antipyrine, D-glucaric acid and indocyanine green elimination in patients with hepatic disorders.
    Traeger A; Horváth T; Rechenbach C; Jávor T
    Int J Clin Pharmacol Res; 1986; 6(3):235-9. PubMed ID: 3744626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver size and indices of drug metabolism in alcoholics.
    Pirttiaho HI; Sotaniemi EA; Ahlqvist J; Pitkänen U; Pelkonen RO
    Eur J Clin Pharmacol; 1978 Mar; 13(1):61-7. PubMed ID: 639835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of various liver diseases on the activity of 2 subtypes of cytochrome P-450].
    Balogh A; Simon HJ; Reinhardt M; Splinter FK; Traeger A
    Dtsch Z Verdau Stoffwechselkr; 1987; 47(1):1-13. PubMed ID: 3582233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of hypoxia and pregnancy on antipyrine metabolism in isolated perfused rat livers.
    Brouwer KL; Vore M
    J Pharmacol Exp Ther; 1985 Sep; 234(3):584-9. PubMed ID: 4032283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man.
    Teunissen MW; van der Veen EA; Doodeman PJ; Breimer DD
    Eur J Clin Pharmacol; 1984; 27(1):99-103. PubMed ID: 6489432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [An attempt at assessment of biotransformation activity in calves' liver on the basis of the rate of antipyrine elimination from saliva].
    Janus K; Baranow-Baranowski S; Jakubowska D
    Pol Arch Weter; 1991; 31(3-4):65-71. PubMed ID: 1842615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Metabolic interactions of propyphenazone].
    Borchert HH; Schuster S; Pfeifer S
    Pharmazie; 1983 Jan; 38(1):48-50. PubMed ID: 6405401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipyrine metabolism and liver function in patients treated with high-dose medroxyprogesterone.
    Rautio A; Kauppila AJ; Tuimala RJ; Sotaniemi EA
    Biomedicine; 1979 Sep; 31(5):135-8. PubMed ID: 508896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research on the eventual enzymatic induction activity of cetiedil in rat and man.
    Larousse C; Kergueris MF; Le Normand Y; Visset J
    Int J Clin Pharmacol Ther Toxicol; 1980; 18(5):195-9. PubMed ID: 7390670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of the capacity of the liver for phenazone biotransformation in patients with uremia on peritoneal dialysis].
    Grzegorzewska A; Lowicki Z; Chmara E; Mrozikiewicz A; Baczyk K
    Pol Tyg Lek; 1990 Apr 16-30; 45(16-18):339-41. PubMed ID: 2235722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spironolactone and enzyme induction in patients with alcoholic cirrhosis.
    Miguet JP; Vuitton D; Thebault-Lucas A; Joanne C; Dhumeaux D
    Gastroenterology; 1980 May; 78(5 Pt 1):996-1000. PubMed ID: 7380205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma high-density lipoproteins and hepatic microsomal enzyme induction. Relation to histological changes in the liver.
    Luoma PV; Sotaniemi EA; Pelkonen RO; Arranto A; Ehnholm C
    Eur J Clin Pharmacol; 1982; 23(3):275-82. PubMed ID: 7173298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.